Sources MHRA Drug Safety Update Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), 5 February 2026 BMJ Semaglutide and NAION, February 2026 Community Pharmacy England MHRA Drug Safety Update: Semaglutide and NAION, 5 February 2026 NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current
62 Sison-YoungR
prescribing information for Ozempic (semaglutide), the most common adverse reactions are gastrointestinal (nausea, vomiting, diarrhea, abdominal pain, constipation)
Mounjaro uses a different ingredient, tirzepatide, which targets both GLP-1 and GIP hormones, potentially offering additional benefits for weight loss and diabetes control
If this is causing distress, its worth discussing with a therapist or counsellor
A clinical trial of isradipine: what went wrong